Matches in Nanopublications for { ?s ?p "DDI between Toremifene and Dolasetron - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. [drugbank_resource:DB00539_DB00757]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00539_DB00757 label "DDI between Toremifene and Dolasetron - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. [drugbank_resource:DB00539_DB00757]" assertion.